Phase 2 N=45 Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus
Epidermoid Carcinoma · Anus
Primary: Percentage of Patients With Complete Response to Treatment — 30; 10; 0; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 A Safety and Tolerability of Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial Neoplasia
Anal Intraepithelial Neoplasia (AIN) · High-grade Squamous Intraepithelial Lesions (HSIL)
Primary: Related Adverse Events — 1; 1 number of participants
N/A N=46 Anal Human Papillomavirus in Inflammatory Bowel Disease Study
Inflammatory Bowel Disease (IBD) · Ulcerative Colitis (UC) · Crohn's Disease (CD)
Primary: Number of Participants With Anal HPV of Any Type, Single Type, and Multiple Types — 41; 16; 25 participants
Phase 2 N=53 Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy
Ulcerative Colitis
Primary: Detected Intraepithelial Neoplasia — 0.2 Number of detected IN
N/A N=276 Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Anal Cancer · HIV Infection · Human Papilloma Virus Infection
Primary: Specificity of Each Other Methods of HSIL Detection for APTIMA Assay — 116 Participants
N/A N=26 Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
N/A N=718 The Prevent Anal Cancer Palpation Study
Anal Cancer
Primary: Concordance Between Self-examination and Clinician Examination — 234; 247 Participants
Phase 2 N=63 Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer
Anal Cancer
Primary: Local Failure Rate at 3 Years — 0.259; 0.353 proportion of participants — p=0.218
Phase 2 N=32 Pembrolizumab in Metastatic Anal Cancer
Anal Cancer
Primary: Overall Response Rate — 11.1 probability
Phase 2 N=63 Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer
Anal Cancer
Primary: Percentage of Subjects With Acute Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) ≥ Grade 2 as Defined by CTCAE v3.0 (Common Terminology Criteria for…
Phase 2 N=36 A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
Anal Cancer · Rectal Cancer
Primary: Percentage of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 — 2.8 percentage of participants
N/A N=80 Video-assisted Anal Fistula Treatment Versus Seton in the Management of High Peri Anal Fistula
Post Operative Pain · Recurrence
Primary: Number of Participants With Recurrence of Disease or Fistula — 5; 10 Participants
Phase 3 N=120 Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
Anal Cancer · Neoplasm of Uncertain Malignant Potential · Nonneoplastic Condition
Primary: Complete Response Through 1 Year — 38; 16 participants
Phase 2 N=20 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
Anal Cancer
Primary: 2 Year Failure Free Survival — 20 participants
N/A N=12 Studies in Patients With Low Anterior Resection Syndrome (LARS)
Anterior Resection Syndrome · Bowel Dysfunction
Primary: Change of Anorectal Pressure Assessed With the Fecobionics Device — 9.8 cmH2O
N/A N=121 The Role of Biofeedback in Improving Continence After Anterior Resection
Rectal Neoplasms · Fecal Incontinence · Aged
Primary: Cleveland Clinic Incontinence (CCI) Score — 4.2; 3.7; 1.2; -0.7 score on a scale — p=0.54
N/A N=240 The Prevent Anal Cancer Self-Swab Study
Anal Cancer
Primary: Compliance With Annual Anal HPV DNA Screening — 107; 89; 13; 31 Participants
N/A N=63 Idiopathic Hypertensive Anal Canal: a Place of Internal Sphincterotomy
Hypertensive Anal Canal
Primary: Effect of Closed Lateral Sphincterotomy and Chemical Sphincterotomy on Hypertensive Anal Canal
N/A N=269 Complete Histologic Resection of Adenomatous Polyps?
Adenomatous Polyps
Primary: Percent of Incompletely Resected Adenomatous Polyps — 10.1 percentage of incomplete resection
Phase 2 N=94 A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)
Squamous Cell Carcinoma of Anal Canal
Primary: Objective Response Rate (ORR) — 13.8 percentage of participants
N/A N=40 An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Phase 2 N=70 Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream
Anus Neoplasms
Primary: Final Response of Anal High-grade Squamous Intraepithelial Lesions (HSIL) — 3; 0; 7; 3 participants — p=.042
N/A N=31 Correlation of Anal Acoustic Reflectometry Parameters With Degree of Rectal Intussusception and Prolapse
Pelvic Floor Disorders
Primary: Opening Pressure — 56.35; 39.01; 23.42 cmH20
Phase 2 N=108 Topical NVN1000 for the Treatment of External Genital and Perianal Warts
Genital Warts · Perianal Warts
Primary: Efficacy: Complete Clearance of Baseline External Genital and Perianal Warts at or Before Week 12 — 2; 5; 2; 10 Participants
Phase 2 N=58 NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
Rectal Cancer
Primary: Percentage of Organ Preservation — 57 percentage of participants
Phase 4 N=62 NITI CAR27 (ColonRing) Compression Anastomosis in Colorectal Surgery
Colonic Neoplasms · Rectal Neoplasms · Diverticulitis
Primary: Anastomotic Leakage — 0 participants
Phase 2 N=124 Efficacy of Delayed Coloanal Anastomosis for Medium and Lower Rectum Cancer Treatment. Phase 2 Clinical Trial (CASCADOR)
Medium and Lower Rectal Cancer
Primary: Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among 2SCA — 1 Participants
Phase 3 N=4,446 Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
Anal Cancer · High-grade Squamous Intraepithelial Lesion · HIV Infection
Primary: Anal Cancer Incidence — 173; 402 cases per 100,000 person years
N/A N=100 A Prospective, Multi-center, Observational Study of the Use of Permacol™ Collagen Paste to Treat Anorectal Fistulas
Anorectal Fistulas
Primary: Fistula Healing in Patients at 6 Months Following Surgery — 56.7; 43.3 percentage of participants
Phase 3 N=91 Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions
Anal Intraepithelial Neoplasia · High-grade Squamous Intraepithelial Lesion · HIV Infection
Primary: Percentage of Participants Achieving Complete Response in 5-FU Arm and Observation Arm Using ITT Population — 5; 9 Participants — p=0.1877